Influenza epidemiology and influenza vaccine effectiveness during the 2015-2016 season: results from the Global Influenza Hospital Surveillance Network
Por:
Puig-Barberà J, Mira-Iglesias A, Burtseva E, Cowling BJ, Serhat U, Ruiz-Palacios GM, Launay O, Kyncl J, Koul P, Siqueira MM, Sominina A and Global Influenza Hospital Surveillance Network
Publicada:
14 may 2019
Categoría:
Infectious diseases
Resumen:
BackgroundThe Global Influenza Hospital Surveillance Network is an international platform whose primary objective is to study severe cases of influenza requiring hospitalization.MethodsDuring the 2015-2016 influenza season, 11 sites in the Global Influenza Hospital Surveillance Network in nine countries (Russian Federation, Czech Republic, Turkey, France, China, Spain, Mexico, India, and Brazil) participated in a prospective, active-surveillance, hospital-based epidemiological study. Influenza infection was confirmed by reverse transcription-polymerase chain reaction. Influenza vaccine effectiveness (IVE) against laboratory-confirmed influenza was estimated using a test-negative approach.Results9882 patients with laboratory results were included of which 2415 (24.4%) were positive for influenza, including 1415 (14.3%) for A(H1N1)pdm09, 235 (2.4%) for A(H3N2), 180 (1.8%) for A not subtyped, 45 (0.5%) for B/Yamagata-lineage, 532 (5.4%) for B/Victoria-lineage, and 33 (0.3%) for B not subtyped. Of included admissions, 39% were<5years of age and 67% had no underlying conditions. The odds of being admitted with influenza were higher among pregnant than non-pregnant women (odds ratio, 2.82 [95% confidence interval (CI), 1.90 to 4.19]). Adjusted IVE against influenza-related hospitalization was 16.3% (95% CI, 0.4 to 29.7). Among patients targeted for influenza vaccination, adjusted IVE against hospital admission with influenza was 16.2% (95% CI, -3.6 to 32.2) overall, 23.0% (95% CI, -3.3 to 42.6) against A(H1N1)pdm09, and-25.6% (95% CI, -86.3 to 15.4) against B/Victoria lineage.ConclusionsThe 2015-2016 influenza season was dominated by A(H1N1)pdm09 and B/Victoria-lineage. Hospitalization with influenza often occurred in healthy and young individuals, and pregnant women were at increased risk of influenza-related hospitalization. Influenza vaccines provided low to moderate protection against hospitalization with influenza and no protection against the predominant circulating B lineage, highlighting the need for more effective and broader influenza vaccines.
Filiaciones:
:
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana, FISABIO, Valencia, Spain.
:
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana, FISABIO, Valencia, Spain
Burtseva E:
Ivanovsky Institute of Virology FSBI "N.F, Gamaleya NRCEM" Ministry of Health, Moscow, Russian Federation
Cowling BJ:
School of Public Health, Li Ka Shing Faculty of Medicine, Hong Kong, Hong Kong, Special Administrative Region of China
Serhat U:
Turkish Society of Internal Medicine, Ankara, Turkey
Ruiz-Palacios GM:
Salvador Zubirán National Institute of Medical Sciences and Nutrition (INCMNSZ), Vasco de Quiroga 15, Belisario Domínguez Sección 16, 14080, Tlalpan, CDMX, Mexico
Launay O:
INSERM, F-CRIN, Réseau National d'Investigation Clinique en Vaccinologie (I-REIVAC), CIC Cochin Pasteur, Paris, France and Université Paris Descartes, Sorbonne Paris Cité and Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France
Kyncl J:
National Institute of Public Health, Prague, Czech Republic
Koul P:
Department of Internal and Pulmonary Medicine, Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Soura, Bemina, Srinagar, Jammu Kashmir, 190011, India
Siqueira MM:
FIOCRUZ, Rio de Janeiro, Brazil
Sominina A:
Research Institute of Influenza, WHO National Influenza Centre of Russia and Ministry of Healthcare of the Russian Federation, St. Petersburg, Russian Federation
Green Published, gold
|